Post-Operative Nausea and Vomiting Market Report 2026

The post-operative nausea and vomiting market size has grown strongly in recent years. It will grow from $2.25 billion in 2025 to $2.41 billion in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to increasing surgical procedure volumes, wider use of general anesthesia, availability of serotonin antagonist drugs, expansion of hospital surgical infrastructure, improved post-operative care guidelines.

The post-operative nausea and vomiting market size is expected to see strong growth in the next few years. It will grow to $3.13 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to growing demand for personalized anesthesia care, rising adoption of preventive antiemetic regimens, expansion of ambulatory surgical centers, increasing focus on patient satisfaction metrics, growing investments in perioperative care innovation. Major trends in the forecast period include increasing adoption of multimodal ponv management strategies, rising use of combination antiemetic therapies, growing focus on risk-stratified treatment protocols, expansion of non-pharmacological interventions, enhanced emphasis on patient comfort and recovery.

The increasing number of surgical procedures is expected to drive the growth of the post-operative nausea and vomiting market in the coming years. Surgical procedures are medical interventions that involve the use of instruments to diagnose, treat, or remove damaged tissues, organs, or abnormalities through incision or manipulation. The volume of surgical procedures is rising due to advancements in medical technology, which have improved surgical safety, effectiveness, and the adoption of minimally invasive techniques, thereby increasing patient acceptance and expanding clinical applications. Management of post-operative nausea and vomiting supports surgical procedures by enhancing patient comfort, shortening recovery time, reducing the risk of complications, ensuring smoother post-operative care, and ultimately improving overall surgical outcomes. For instance, in November 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, during the 2023-24 period, 771,600 patients were admitted for surgery from public hospital elective surgery waiting lists, reflecting a 4.9% increase compared to 2022-23. Therefore, the growing number of surgical procedures is contributing to the expansion of the post-operative nausea and vomiting market.

The expansion of healthcare infrastructure is also expected to propel the growth of the post-operative nausea and vomiting market going forward. Healthcare infrastructure includes the physical facilities, equipment, and organizational systems that enable the delivery of healthcare services, such as hospitals, surgical centers, and medical technologies. Growth in healthcare infrastructure is largely driven by rising patient populations and increased demand for surgical care, as aging populations and the prevalence of chronic diseases necessitate greater hospital capacity and more surgical interventions. The establishment of new hospitals and surgical facilities increases the number of surgeries performed, which in turn raises the likelihood of post-operative complications that require antiemetic management and treatment. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the United States had 6,129 hospitals, representing a 0.591% increase compared to the previous year, when there were 6,093 hospitals. Therefore, the expansion of healthcare infrastructure is driving the growth of the post-operative nausea and vomiting market.

Major companies operating in the post-operative nausea and vomiting market are concentrating on the development of advanced injectable medications, including regulatory-approved commercial launches of pharmaceutical injectables, to strengthen antiemetic therapy in clinical environments. A regulatory-approved commercial launch of a pharmaceutical injectable refers to the introduction of an injectable drug that has received approval from the FDA or other regulatory authorities for clinical use after meeting all compliance and approval requirements. For instance, in July 2024, Avenacy, a US-based specialty pharmaceutical company, introduced Palonosetron Hydrochloride Injection in 0.25 mg/5 mL single-dose vials to help healthcare providers reduce dosing errors and enhance patient safety. This injectable medication is indicated for the prevention of nausea and vomiting associated with chemotherapy and for the management of post-operative nausea and vomiting for up to 24 hours after surgery, offering a dependable treatment option for patients at risk of these conditions.

Major companies operating in the post-operative nausea and vomiting market are Pfizer Inc., Merck KGaA, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Baxter Corporation, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Inc., Fresenius Kabi AG, Eisai Co. Ltd., Dr. Reddy's Laboratories, Cipla Ltd., Alkem Laboratories Ltd., Eagle Pharmaceuticals Inc., Helsinn Healthcare SA, Heron Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Johnson And Johnson, Sanofi, Aurobindo Pharma Ltd., Lupin Limited.

North America was the largest region in the post-operative nausea and vomiting market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-operative nausea and vomiting market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the post-operative nausea and vomiting market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the post-operative nausea and vomiting market by increasing costs of imported active pharmaceutical ingredients, injectable formulations, transdermal patches, and drug delivery devices. Hospitals and surgical centers in North America and Europe are most affected due to reliance on imported medications, while Asia-Pacific faces cost pressure on pharmaceutical manufacturing. These tariffs are contributing to higher treatment costs and procurement delays. However, they are also encouraging domestic drug production, local formulation development, and supply chain diversification.

The post-operative nausea and vomiting market research report is one of a series of new reports that provides post-operative nausea and vomiting market statistics, including post-operative nausea and vomiting industry global market size, regional shares, competitors with a post-operative nausea and vomiting market share, detailed post-operative nausea and vomiting market segments, market trends and opportunities, and any further data you may need to thrive in the post-operative nausea and vomiting industry. This post-operative nausea and vomiting market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Post-operative nausea and vomiting (PONV) is a frequent complication that develops within 24 to 48 hours following surgery and is commonly associated with anesthesia, pain-relieving medications, or the body’s response to surgical stress. It can have a considerable impact on patient recovery by causing discomfort, delaying healing, and increasing the risk of complications such as dehydration or electrolyte imbalances.

The primary treatment categories for post-operative nausea and vomiting include serotonin antagonists, steroids, dopamine antagonists, neurokinin NK-1 receptor antagonists, non-pharmacological treatments, and others. Serotonin antagonists are medications that inhibit serotonin receptors, thereby blocking nausea and vomiting signals in the brain. These treatments are administered through various routes including oral, intravenous, transdermal, and others, and are used across different patient groups such as pediatric, adult, and geriatric patients. They are applied in multiple surgical procedures including orthopedic surgery, gynecological surgery, general surgery, cardiac surgery, and ophthalmic surgery, and are utilized by end users such as hospitals, ambulatory surgical centers, specialty clinics, and others.

The post-operative nausea and vomiting market consists of revenues earned by entities by providing services such as patient monitoring, anesthesia management, antiemetic drug administration, postoperative care, and clinical counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The post-operative nausea and vomiting market also includes sales of antiemetic drugs, intravenous fluids, nausea relief patches, oxygen therapy devices, and acupuncture kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.